24
May

08:00 AM ET

Medicinal Chemistry

Name: Medicinal Chemistry Strategy Meeting Princeton
Start: 2023-05-24T08:00
End: 2023-05-24T17:50
Location: Hyatt Regency Princeton

Strategy Meeting East Coast USA 2023

Reinvigorating Productivity in Pharma & Biotech R&D Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms

Hyatt Regency Princeton

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Medicinal Chemistry Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Medicinal Chemistry professionals from across the East Coast, in Princeton, New Jersey, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Meet Our 2023 Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Medicinal Chemistry strategy meeting.

Abhijat Vatsyayan

Head of AI and Innovation Taiho Oncology

Aziz Nazha

Executive Director, Early Drug Development Incyte

Brahma Ghosh

Head, Chemical Biology Johnson & Johnson

Christopher Cooper

Head of Medicinal Chemistry TB Alliance

Ed Kesicki

Associate Vice President – Discovery Strategy and Operation Loxo Oncology

Deborah Rothman

Executive Director, Chemical Biology Merck

Gunaretnam Rajagopal

Venture Partner Samsara Biocapital

<p><strong>Guna</strong> has experience in applying Informatics & Analytics across the entire drug discovery & development pipeline to advance the search and development of safe and effective medicines. His training and expertise encompass the fields of Data Sciences, AI/Machine Learning, Bioinformatics, Computational, Systems Biology & Pharmacology, Genetics & Genomics, High Performance Computing and Theoretical & Computational Physics. He received his PhD in Computational & Theoretical Physics from Georgia Tech in 1991. Guna was an Assistant Director of Research at the Cavendish (1996-2000) and elected a Fellow of Jesus College Cambridge (1996-2000). He moved to Singapore to be the founding Executive Director of the Bioinformatics Institute (2000-2007) that coordinated and supported biomedical computing & informatics supporting public & pharmaceutical R&D institutes at the BIOPOLIS. In 2008, he moved to Rutgers University to head the Bioinformatics & Systems Biology program at the Rutgers Cancer Institute of New Jersey (a NCI-designated comprehensive cancer center), with a joint appointment as Adjunct Professor at the Robert Wood Johnson Medical School and as a Member of the School of Natural Sciences, Institute for Advanced Studies in Princeton (2007-2012). In 2012, he was recruited to Johnson & Johnson to lead efforts to develop and deploy Computational, Informatics and Data Science infrastructure & capabilities to support global programs in basic, clinical, translational research across all therapeutic and functional areas. After ten years at J&J,</p>

Huijun Wang

Head of Computational Drug Design Deerfield Management

Jing Su

VP, Head of Discovery Chemistry IONOVOBIO

John Apathy

Chief Solution Officer XponentL Data

Mike Palovich

Chief Scientific Officer and Head of Drug Discovery Cyclica

Nikolaos Tezapsidis

President & CEO Neurotez Inc.

Sandro Belvedere

Vice President, Chemistry Avicenna Biosciences, Inc.

Tina (Kramer) Garyantes

Chief Operating Officer Linnaeus Therapeutics

Thomas Nittoli

Senior Director Regeneron

First name	Last name	Job title	Company name	Photo URL	Bio Position
Abhijat	Vatsyayan	Head of AI and Innovation	Taiho Oncology	https://proventainternational.com/wp-content/uploads/2023/03/Abhijat-Vatsyayan.jpg	Trained as an aerospace engineer Abhijat has had a career spanning over 23 years most of it dedicated to helping to bring life extending medicines to patients through the use of technology in this 20 years working at pharmaceutical companies he collaborates with individuals from diverse backgrounds applying analytical design and creative problem solving skills to the complex challenge of drug development abhijat also has a foundational understanding of artificial intelligence including machine learning and has built simplified deep learning frameworks to educate and present machine learning concepts finally he is also a proud co founder of multiple failed startups.
Aziz	Nazha	Executive Director, Early Drug Development	Incyte	https://proventainternational.com/wp-content/uploads/2023/05/Aziz-Nazha.jpg
Brahma	Ghosh	Head, Chemical Biology	Johnson & Johnson	https://proventainternational.com/wp-content/uploads/2023/05/Brahma-Ghosh.jpg	Dr. Brahma Ghosh is currently the Head of Chemical Biology within Global Discovery Chemistry, JanssenR&D, Johnson and Johnson. In this role, he is responsible for driving the department’s Chemical Biologystrategy toward addressing diverse questions related to compound progression across discovery stage-gates. These include deconvoluting or discovering targets and novel MOAs, proteome-wide ligandabilityassessment, pathway and interactome mapping, and novel chemical probe discovery. At this role, Dr.Ghosh also leads the department’s Irreversible Covalent Inhibitor discovery effort. Dr. Ghosh is the co-inventor of the covalent small-molecule, SKBG-1(R), the first ever reported chemical probe for a DHFBS-family of RNA-binding protein.
Christopher	Cooper	Head of Medicinal Chemistry	TB Alliance	https://proventainternational.com/wp-content/uploads/2023/05/Christopher-Cooper.jpg
Ed	Kesicki	Associate Vice President – Discovery Strategy and Operation	Loxo Oncology	https://proventainternational.com/wp-content/uploads/2023/03/Ed-Kesicki.jpg
Deborah	Rothman	Executive Director, Chemical Biology	Merck	https://proventainternational.com/wp-content/uploads/2023/03/Deborah-Rothman.jpg
Gunaretnam	Rajagopal	Venture Partner	Samsara Biocapital	https://proventainternational.com/wp-content/uploads/2022/08/Gunaretnam-Rajagopal.jpg	Guna has experience in applying Informatics & Analytics across the entire drug discovery & development pipeline to advance the search and development of safe and effective medicines. His training and expertise encompass the fields of Data Sciences, AI/Machine Learning, Bioinformatics, Computational, Systems Biology & Pharmacology, Genetics & Genomics, High Performance Computing and Theoretical & Computational Physics. He received his PhD in Computational & Theoretical Physics from Georgia Tech in 1991. Guna was an Assistant Director of Research at the Cavendish (1996-2000) and elected a Fellow of Jesus College Cambridge (1996-2000). He moved to Singapore to be the founding Executive Director of the Bioinformatics Institute (2000-2007) that coordinated and supported biomedical computing & informatics supporting public & pharmaceutical R&D institutes at the BIOPOLIS. In 2008, he moved to Rutgers University to head the Bioinformatics & Systems Biology program at the Rutgers Cancer Institute of New Jersey (a NCI-designated comprehensive cancer center), with a joint appointment as Adjunct Professor at the Robert Wood Johnson Medical School and as a Member of the School of Natural Sciences, Institute for Advanced Studies in Princeton (2007-2012). In 2012, he was recruited to Johnson & Johnson to lead efforts to develop and deploy Computational, Informatics and Data Science infrastructure & capabilities to support global programs in basic, clinical, translational research across all therapeutic and functional areas. After ten years at J&J,
Huijun	Wang	Head of Computational Drug Design	Deerfield Management	https://proventainternational.com/wp-content/uploads/2023/05/Huijun-Wang.jpg	Huijun Wang, Ph.D., is the Head of Computational Drug Design, Deerfield Discovery and Development, and joined the Firm in 2022. Prior to Deerfield, Dr. Wang was most recently Director, Computational Drug Design at Agios Pharmaceuticals. Before Agios, she was an Associate Principal Scientist, Modeling and Informatics at Merck and a Senior Scientist at Pfizer. Dr. Wang is an expertise in computational drug design including chemical biology, virtual screening, AI/ML, structure/ligand-based design, ADMET prediction, etc. Dr. Wang has over 18 years experiences in AI/ML, NLP, FAIR data management, cheminformatics, bioinformatics, and their applications in drug discovery.
Jing	Su	VP, Head of Discovery Chemistry	IONOVOBIO	https://proventainternational.com/wp-content/uploads/2023/05/Jing-Su.jpg	Jing Su got his Ph.D from University of Chicago, did Postdoc work at Columbia University before he joined Legacy Schering-Plough/Merck where As a Director of Chemistry, his research spanned from early Hit Finding, Lead ID to Lead Op in various therapeutic areas (CV, CNS, Infectious Diseases, Oncology). He also worked as an External Chemistry Lead, guiding external chemists on Discovery projects as well as Process Chemistry projects. His expertise is in Structure-based Drug Design, Infectious Disease (in particular, antibiotic research). Currently he serves as Head of Discovery Chemistry at IonovaBio, continuing his journey of Drug Discovery.
John	Apathy	Chief Solution Officer	XponentL Data	https://proventainternational.com/wp-content/uploads/2023/05/John-Apathy.jpg
Mike	Palovich	Chief Scientific Officer and Head of Drug Discovery	Cyclica	https://proventainternational.com/wp-content/uploads/2023/05/Mike-Palovich.jpg	Mike Palovich has been doing small molecule drug discovery for 25+years, across a variety of roles, activities and interests. He is currently CSO and Head of Drug Discovery at Cyclica. Prior to Cyclica, Mike spent ~24 years in small molecule drug discovery at GSK during which he held various leadership roles across the drug discovery organization. While at GSK, he held or led a variety of scientific drug discovery teams and efforts, as well as councils and initiatives aimed at improving drug discovery productivity and attrition. Over the past ~10-years, Mike has been pursuing the development and application of AI/ML technologies to the drug discovery process.
Nikolaos	Tezapsidis	President & CEO	Neurotez Inc.	https://proventainternational.com/wp-content/uploads/2023/02/Nikolaos-Tezapsidis.jpg	Nikolaos Tezapsidis, PhD is the Founder, President, CEO, and Chairman of Neurotez, Inc., a pioneering biotechnology company established in 2005. With over 18 years of hands-on biomedical research experience, he has spearheaded the development of Memtin, a recombinant human Leptin product aimed at hormone replacement therapy for hypoleptinemic prodromal Alzheimer’s patients. Under his leadership, Neurotez raised $5 million through non-dilutive capital, secured private investments, and built a robust patent portfolio with over 20 issued and pending patents. A distinguished researcher, he has authored 50+ peer-reviewed publications and received accolades such as the InvestAcure Coin Award for advancements in Alzheimer’s treatment
Sandro	Belvedere	Vice President, Chemistry	Avicenna Biosciences, Inc.	https://proventainternational.com/wp-content/uploads/2021/09/Sandro-Belvedere.jpg	Dr. Belvedere is Vice President of Chemistry at Avicenna Biosciences. Bio. Dr. Belvedere is an experienced research and development leader, having successfully delivered clinical candidates and directed programs across a broad range of therapeutic areas. Dr. Belvedere’s previous drug development experience includes directing discovery, development, and manufacturing programs at Forkhead Biotherapeutics and ARMGO Pharma, and work on central nervous system targets at GlaxoSmithKline. In addition, at Aton Pharma, Dr. Belvedere contributed to the discovery of new histone deacetylase inhibitors, leading to the oncology drug SAHA (Vorinostat). He is a named inventor on twenty-one United States patents. Dr. Belvedere holds a Ph.D. in chemistry from Columbia University, a Master of Science degree in chemistry from the University of Rochester, and a graduate degree (Laurea) from the University of Rome.
Tina	(Kramer) Garyantes	Chief Operating Officer	Linnaeus Therapeutics	https://proventainternational.com/wp-content/uploads/2023/03/Tara-Lehner-1.jpg
Thomas	Nittoli	Senior Director	Regeneron	https://proventainternational.com/wp-content/uploads/2023/04/Thomas-Nittoli.jpg

Abhijat Vatsyayan, Aziz Nazha, Brahma Ghosh, Christopher Cooper, Ed Kesicki, Deborah Rothman, Gunaretnam Rajagopal, Huijun Wang, Jing Su, John Apathy, Mike Palovich, Nikolaos Tezapsidis, Sandro Belvedere, Tina (Kramer) Garyantes, Thomas Nittoli

See the agenda and facilitator line-up. Download the strategy meeting brochure for full details.

DOWNLOAD THE BROCHURE

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

There’s only so much you can learn from presentations and lectures. Instead, our interactive Roundtable Discussions let you debate the topics that really matter.

Senior Decision Makers

All our Strategy Meetings are aimed at director-level and above. Discover how your peers are tackling the industries biggest challenges and have your thoughts heard.

Personalised Agendas

Pick the roundtable discussions that you want to be part of. Simply choose your sessions and we’ll create a personalised agenda just for you.

Private and Intimate Networking

Small group discussions, private meetings, networking drink – however you choose to make those important connections, our Strategy Meetings have the solution.

Past Agenda

See Which Topics Are Discussed at the Strategy Meeting

09:00

Roundtable Tracks

AI/ML Evaluating the Effectiveness of Computer-Aided Drug Design, Artificial Intelligence and Machine Learning Tools In Fragment-Based Lead Discovery Innovative and Emerging Modalities Integrating Artificial Intelligence (AI) and Machine Learning (ML) to DNAEncoded Library (DEL) For Accelerating Small Drug Discovery Chemical Biology and Undruggables Utilizing The New Warheads: Strategic Ways Of Developing Targeted Covalent Drugs Hit Identification / Lead Optimization Leveraging Predictive Model Techniques To Accelerate Hit-To-Lead Optimization Integrated Drug Discovery Discovering New Drug Discovery Endpoints: Challenges And Opportunities Investment, Private Equity & Venture Capital Partnerships How strategic R&D partnership and alliances can fast track R&D projects in a co-development program

11:10

Roundtable Tracks

AI/ML Overcoming Challenges And Achieving Resilience: The Future of Biotech and Biopharma – AI-Guided In Drug Discovery and Development Innovative and Emerging Modalities Evaluation of Strategies for Drug-Drug Interaction Assessment To Guide Therapeutic Proteins For Biopharmaceutical Industry Chemical Biology and Undruggables Potential Treatment For Rare Diseases: Innovative Techniques To Leverage Molecular Glues To Modify Protein-Protein Interactomes and Interactions Hit Identification / Lead Optimization Investigating Best Strategies To Accelerate The Progress of Compounds From Hit Identification Into Lead Optimization Integrated Drug Discovery Overview of Fragment-Based Drug Discovery for Productivity and Improvement: Is There Panache Behind the Problems? Investment, Private Equity & Venture Capital Partnerships Targeting unmet medical needs as an investment strategy for 2023 and beyond?

13:40

Roundtable Tracks

AI/ML Approaches to Drug Design, Development, and Discovery: Looking at Challenges, Limitations, and Benefits for the Pharmaceutical and Biotechnology Industries Innovative and Emerging Modalities Big Drugs, Little Drugs – Exploring The Power of Large Molecule Improvements In Discovering Novel Drug Therapies Chemical Biology and Undruggables Developing PROTAC Drugs: Fabricating Strategies for DMPK and ADMET To Overcome Challenges And Limitations Hit Identification / Lead Optimization Overlooked Components Of Drug Discovery/Optimization That Contributes To Clinical Drug Development Failure Rates: True Target Validation And Current Drug Optimization – Best Approach To Eradicate These Difficulties Integrated Drug Discovery Enabling Scientific Development Towards Goals: Managing And Balancing The Internal And External Drug Development Capabilities Investment, Private Equity & Venture Capital Partnerships Why novel small molecule constructs for previously intractable targets in the human proteome are attracting the investor community?

15:50

Roundtable Tracks

AI/ML Integrating AI/ML and Deep Learning Tools To Achieve Higher Accuracy For Predicting ADMET and DMPK Properties For Early Phase Drug Development Innovative and Emerging Modalities The Most Recent Advancements in Small Molecule Drug Design, Development, and Synthesis In Drug Bioavailability Chemical Biology and Undruggables The Effective Designs and Optimization of PROTACs Benefits from Deep Learning and Molecular Simulations Hit Identification / Lead Optimization Understanding The Future Of High Throughput Screening And How We Might Be Able To Reach Undruggable Targets Integrated Drug Discovery The Future Of Computer-Aided Drug Design (CADD) In Various Stages Of The Drug Development Pipelines, As Well As Pharma-Technological Advances Investment, Private Equity & Venture Capital Partnerships The Drug Discovery outsourcing market is on target to be worth $6.3 Billion By 2030? What do the next 7 years look like? Future insights and trends.

Become an official strategy meeting partner

Whatever your business needs, we can help. Get in touch for partnering opportunities

I’D LIKE TO PARTNER

Press play to hear what your colleagues had to say...

Quick Links

Want to find out more?

Find out more details about our Strategy Meetings and other news and events.

Here To Help

Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Princeton

Medicinal Chemistry

Strategy Meeting East Coast USA 2023

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Hyatt Regency Princeton

Fresh Medicinal Chemistry Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Meet Our 2023 Facilitators

Abhijat Vatsyayan

Aziz Nazha

Brahma Ghosh

Christopher Cooper

Ed Kesicki

Deborah Rothman

Gunaretnam Rajagopal

Huijun Wang

Jing Su

John Apathy

Mike Palovich

Nikolaos Tezapsidis

Sandro Belvedere

Tina (Kramer) Garyantes

Thomas Nittoli

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

Senior Decision Makers

Personalised Agendas

Private and Intimate Networking

Past Agenda

See Which Topics Are Discussed at the Strategy Meeting

Opening Keynote

Roundtable

Roundtable Tracks

Networking/1-1 Meetings

Roundtable

Roundtable Tracks

Networking Lunch

Roundtable

Roundtable Tracks

Networking/1-1 Meetings

Keynote Presentations

Roundtable

Roundtable Tracks

Networking/1-1 Meetings

Drinks Reception

Our Co-Host Sponsor

Our Key Opinion Leader

Become an official strategy meeting partner

Press play to hear what your colleagues had to say...

Want to find out more?

Here To Help

Select days you wish to attend You can add multiple days

Daily Delegate Rate includes:

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Your Address

About Your Company

This is required field*

Bone/Osteoporosis

Immunology

Orthopaedics

Cardiovascular

Infectious diseases

Pulmonology

CNS

Inflammation

Hyatt Regency Princeton